Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications who had progressed on prior immune ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

Northwestern Medicine investigators have discovered new intracellular mechanisms that help specialized immune cells adapt and ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from ...

A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

Despite the efforts of the scientific community, cancer is still a leading cause of death worldwide. Immunotherapy, a ground-breaking strategy for cancer ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

This Research Topic is the second volume of the “Immune Responses Against Tumors - From the Bench to the Bedside” Community Series. Please see Volume I ...